<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02974439</url>
  </required_header>
  <id_info>
    <org_study_id>HN-LD</org_study_id>
    <nct_id>NCT02974439</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Amlodipine and Norvasc Under Fasting and FED Conditions in Chinese Healthy Volunteers</brief_title>
  <official_title>An Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence Study of Amlodipine and Norvasc Under Fasting Condition Sand Under Non-fasting(FED) Conditions in Chinese Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Haini Pharmaceutical Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Haini Pharmaceutical Co., Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the pharmacokinetics and bioequivalence of Amlodipine Besylate Tablets 5
      mg versus Norvasc 5 mg tablets administered as 5 mg tablet in healthy volunteers with a
      washout period of 14 days
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study design is an Open-Label Randomized, Single-Dose, 2-way Crossover Bioequivalence
      Study with a washout period of 14 days. During each session, the subjects will be
      administered a single dose of 5mg amlodipine (one LANDI-Amlodipine Tablet 5mg or one Norvasc
      Tablet 5mg) under fasting and FED conditions.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 23, 2016</start_date>
  <completion_date type="Actual">March 21, 2017</completion_date>
  <primary_completion_date type="Actual">March 21, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Bioequivalence based on Peak Plasma Concentration (Cmax)</measure>
    <time_frame>144 hours</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioequivalence based on Area under the plasma concentration versus time curves (AUC)</measure>
    <time_frame>144 hours</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Bioequivalence</condition>
  <arm_group>
    <arm_group_label>LANDI-Amlodipine Besylate Tablet 5mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>During the study session, healthy subjects will be administered a single dose of LANDI-AmlodipineTablet 5mg under fasting and FED conditions.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Norvasc Tablets 5mg</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>During the study session, healthy subjects will be administered a single dose of Norvasc Tablets 5mg under fasting and FED conditions.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LANDI-Amlodipine Besylate Tablet 5mg</intervention_name>
    <description>LANDI-Amlodipine Besylate Tablet 5mg is a generic product manufactured by YangTZE River Pharmaceutical Group Shanghai Haini Pharmaceutical Co., Ltd.</description>
    <arm_group_label>LANDI-Amlodipine Besylate Tablet 5mg</arm_group_label>
    <other_name>Amlodipine Tablet 5mg</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Norvasc Tablets 5mg</intervention_name>
    <description>Norvasc Tablet 5mg will be used as a comparator drug for the BE study.</description>
    <arm_group_label>Norvasc Tablets 5mg</arm_group_label>
    <other_name>Amlodipine Tablet 5mg</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy adult volunteers of 18-40 years old, male or female.

          2. Body mass index (BMI) ranges from 19.0 to 25.0 kg/m2, body weight â‰¥ 50 kg for male and
             45 kg for female.

          3. No history of heart, liver, kidney, gastrointestinal tract diseases, nervous system,
             neural abnormities or metabolic abnormalities; No preparation allergies, serious
             infection or injury, etc.

          4. Medically healthy subjects with clinically normal laboratory profiles and ECGs.

          5. Subjects must agree to take effective contraceptive methods to prevent pregnancy from
             the start of screening until 3 months of last dose administration

          6. Subjects are fully informed and voluntarily consent to participate in this study.

        Exclusion Criteria:

          1. History of allergy or hypersensitivity to amlodipine

          2. Significant history of neurological, cardiovascular, digestive, respiratory, urinary,
             hematological, dysmetabolism or other diseases (such as psychosis) which is
             unfavorable to the study

          3. History of postural hypotension

          4. Blood donation or lost more than 400mL blood within 3 months prior to the study

          5. Use of medications within 2 weeks before the study

          6. Volunteer in any other clinical drug study within 3 months prior to this study

          7. Drug abuse or alcohol abuse (220ml beer /day or &gt;5 times in 2 hours)

          8. Smoker (&gt;10 cigarettes/day)

          9. A positive result in hepatitis B surface antigen (HBsAg), anti-hepatitis C virus (HCV)
             antibodies, a syphilis test, or an human immunodeficiency virus (HIV) test

         10. Abnormal chest X-ray results with clinical significance

         11. Women of childbearing potential, pregnant and lactating women.

         12. Other unfavorable factors diagnosed by investigators.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Yanmei Liu</last_name>
    <role>Principal Investigator</role>
    <affiliation>Shanghai Xuhui Central Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Shanghai Haini Pharmaceutical Co., Ltd.</name>
      <address>
        <city>Shanghai</city>
        <zip>201318</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 17, 2016</study_first_submitted>
  <study_first_submitted_qc>November 25, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 28, 2016</study_first_posted>
  <last_update_submitted>October 12, 2017</last_update_submitted>
  <last_update_submitted_qc>October 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">October 13, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

